. "RIV/00216224:14110/12:00061151!RIV13-MSM-14110___" . "Vnit\u0159n\u00ED l\u00E9ka\u0159stv\u00ED" . . . "chronic hepatitis C; boceprevir; telaprevir"@en . . "7-8" . "14110" . "Trojkombina\u010Dn\u00ED l\u00E9\u010Dba chronick\u00E9 hepatitidy C" . . "1"^^ . "S" . . "1"^^ . . "RIV/00216224:14110/12:00061151" . "Trojkombina\u010Dn\u00ED l\u00E9\u010Dba chronick\u00E9 hepatitidy C" . . "CZ - \u010Cesk\u00E1 republika" . . "175225" . "Trojkombina\u010Dn\u00ED l\u00E9\u010Dba chronick\u00E9 hepatitidy C"@cs . . . "3"^^ . "The 2011 brought a significant change in the chronic hepatitis C treatment. There is a commercial availability of new antiviral agents - telaprevir and boceprevir - in combination with PEG-IFN and ribavirin. This triple combination is significantly more effectice than the standard dual therapy both in naive (approximately 2-fold)and experienced patients (approximately 3-fold)."@en . "V roce 2011 do\u0161lo k z\u00E1sadn\u00ED zm\u011Bn\u011B v mo\u017Enosti l\u00E9\u010Dby chronick\u00E9 infekce virem hepatitidy C (HCV). Podstatou t\u00E9to zm\u011Bny je komer\u010Dn\u00ED dostupnost nov\u00FDch antivirov\u00FDch l\u00E9k\u016F pro terapii chronick\u00E9 infekce HCV \u2013 telapreviru a bocepreviru \u2013v kombinaci s pegylovan\u00FDm interferonem (PEG-IFN) alfa a ribavirinem (RBV). Jak u pacient\u016F dosud antivirov\u011B nel\u00E9\u010Den\u00FDch, naivn\u00EDch, tak u nemocn\u00FDch, u kter\u00FDch klasick\u00E1 l\u00E9\u010Dba PEG-IFN a RBV nevedla k trval\u00E9 eliminaci infekce HCV, je trojkombina\u010Dn\u00ED l\u00E9\u010Dba v\u00FDznamn\u011B \u00FA\u010Dinn\u011Bj\u0161\u00ED ne\u017E kombinace PEG-IFN a RBV. U naivn\u00EDch pacient\u016F je trojkombina\u010Dn\u00ED l\u00E9\u010Dba zhruba dvakr\u00E1t \u00FA\u010Dinn\u011Bj\u0161\u00ED ne\u017E standardn\u00ED l\u00E9\u010Dba PEG-IFN a RBV. U pacient\u016F ji\u017E v minulosti l\u00E9\u010Den\u00FDch PEG-IFN a RBV je efekt trojkombina\u010Dn\u00ED l\u00E9\u010Dby dokonce t\u0159ikr\u00E1t vy\u0161\u0161\u00ED ne\u017E p\u0159i opakov\u00E1n\u00ED l\u00E9\u010Dby PEG-IFN a RBV." . "58" . . . "Trojkombina\u010Dn\u00ED l\u00E9\u010Dba chronick\u00E9 hepatitidy C"@cs . "[C9D6FE7A509F]" . "Triple combination treatment of chronic hepatitis C"@en . "Triple combination treatment of chronic hepatitis C"@en . "Husa, Petr" . "V roce 2011 do\u0161lo k z\u00E1sadn\u00ED zm\u011Bn\u011B v mo\u017Enosti l\u00E9\u010Dby chronick\u00E9 infekce virem hepatitidy C (HCV). Podstatou t\u00E9to zm\u011Bny je komer\u010Dn\u00ED dostupnost nov\u00FDch antivirov\u00FDch l\u00E9k\u016F pro terapii chronick\u00E9 infekce HCV \u2013 telapreviru a bocepreviru \u2013v kombinaci s pegylovan\u00FDm interferonem (PEG-IFN) alfa a ribavirinem (RBV). Jak u pacient\u016F dosud antivirov\u011B nel\u00E9\u010Den\u00FDch, naivn\u00EDch, tak u nemocn\u00FDch, u kter\u00FDch klasick\u00E1 l\u00E9\u010Dba PEG-IFN a RBV nevedla k trval\u00E9 eliminaci infekce HCV, je trojkombina\u010Dn\u00ED l\u00E9\u010Dba v\u00FDznamn\u011B \u00FA\u010Dinn\u011Bj\u0161\u00ED ne\u017E kombinace PEG-IFN a RBV. U naivn\u00EDch pacient\u016F je trojkombina\u010Dn\u00ED l\u00E9\u010Dba zhruba dvakr\u00E1t \u00FA\u010Dinn\u011Bj\u0161\u00ED ne\u017E standardn\u00ED l\u00E9\u010Dba PEG-IFN a RBV. U pacient\u016F ji\u017E v minulosti l\u00E9\u010Den\u00FDch PEG-IFN a RBV je efekt trojkombina\u010Dn\u00ED l\u00E9\u010Dby dokonce t\u0159ikr\u00E1t vy\u0161\u0161\u00ED ne\u017E p\u0159i opakov\u00E1n\u00ED l\u00E9\u010Dby PEG-IFN a RBV."@cs . . "0042-773X" . .